NO322016B1 - Anvendelse av utgangsmaterialer,fremgangsmate for hemisyntese av forbindelser og nye forbindelser - Google Patents

Anvendelse av utgangsmaterialer,fremgangsmate for hemisyntese av forbindelser og nye forbindelser Download PDF

Info

Publication number: NO322016B1
Authority: NO; Norway
Prior art keywords: group; compound; formula; ring; saframycin
Prior art date: 1999-05-14

Application number

NO20015547A

Other languages

English (en)

Norwegian (no)

Other versions

NO20015547D0 (no

NO20015547L (no

Inventor

Carmen Cuevas

Andres Francesch

Carolina Fernandez

Jose Luis Chicharro

Pilar Gallego

Maria Zarzuelo

Fernando De La Calle

Ignacio Manzanares

Marta Perez

Original Assignee

Pharma Mar Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-14

Filing date

2001-11-13

Publication date

2006-08-07

1999-05-14 Priority claimed from GBGB9911345.8A external-priority patent/GB9911345D0/en

1999-08-02 Priority claimed from GBGB9918178.6A external-priority patent/GB9918178D0/en

1999-10-06 Priority claimed from GBGB9923632.5A external-priority patent/GB9923632D0/en

2000-01-17 Priority claimed from GB0001063A external-priority patent/GB0001063D0/en

2001-11-13 Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa

2001-11-13 Publication of NO20015547D0 publication Critical patent/NO20015547D0/no

2002-01-14 Publication of NO20015547L publication Critical patent/NO20015547L/no

2006-08-07 Publication of NO322016B1 publication Critical patent/NO322016B1/no

Links

150000001875 compounds Chemical class 0.000 title claims description 185
238000000034 method Methods 0.000 title claims description 93
239000007858 starting material Substances 0.000 title claims description 30
238000006243 chemical reaction Methods 0.000 claims description 93
-1 hydroxymethylene group Chemical group 0.000 claims description 70
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical group O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 55
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 44
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 41
230000015572 biosynthetic process Effects 0.000 claims description 37
PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 claims description 34
229960000977 trabectedin Drugs 0.000 claims description 29
229930190585 Saframycin Natural products 0.000 claims description 26
125000000468 ketone group Chemical group 0.000 claims description 24
125000002252 acyl group Chemical group 0.000 claims description 23
XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 claims description 22
238000002360 preparation method Methods 0.000 claims description 21
125000004093 cyano group Chemical group *C#N 0.000 claims description 19
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 19
GKUZBRIJGIGFKC-UHFFFAOYSA-N Safracin B Natural products OC1C(N2C)CC3=CC(C)=C(OC)C(O)=C3C2C(C2)N1C(CNC(=O)C(C)N)C1=C2C(=O)C(C)=C(OC)C1=O GKUZBRIJGIGFKC-UHFFFAOYSA-N 0.000 claims description 18
125000000217 alkyl group Chemical group 0.000 claims description 18
GKUZBRIJGIGFKC-XPXFATIHSA-N antibiotic em 5519 Chemical compound C([C@@H](N1C)[C@@H]2O)C3=CC(C)=C(OC)C(O)=C3[C@H]1[C@H](C1)N2[C@@H](CNC(=O)[C@H](C)N)C2=C1C(=O)C(C)=C(OC)C2=O GKUZBRIJGIGFKC-XPXFATIHSA-N 0.000 claims description 18
229910052739 hydrogen Inorganic materials 0.000 claims description 18
125000003118 aryl group Chemical group 0.000 claims description 17
239000001257 hydrogen Substances 0.000 claims description 17
125000006239 protecting group Chemical group 0.000 claims description 17
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 claims description 16
238000003786 synthesis reaction Methods 0.000 claims description 16
125000004432 carbon atom Chemical group C* 0.000 claims description 15
230000008569 process Effects 0.000 claims description 15
239000003153 chemical reaction reagent Substances 0.000 claims description 11
229930194542 Keto Natural products 0.000 claims description 10
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
125000001424 substituent group Chemical group 0.000 claims description 10
BHINEHROXMLHMV-BVRLQDJESA-N C([C@H](N1C)[C@@H]2C#N)C3=CC(C)=C(OC)C(O)=C3[C@@H]1[C@H](C1)N2[C@@H](CNC(=O)[C@H](C)N)C2=C1C(=O)C(C)=C(OC)C2=O Chemical compound C([C@H](N1C)[C@@H]2C#N)C3=CC(C)=C(OC)C(O)=C3[C@@H]1[C@H](C1)N2[C@@H](CNC(=O)[C@H](C)N)C2=C1C(=O)C(C)=C(OC)C2=O BHINEHROXMLHMV-BVRLQDJESA-N 0.000 claims description 9
229930188681 renieramycin Natural products 0.000 claims description 9
125000003545 alkoxy group Chemical group 0.000 claims description 8
125000003710 aryl alkyl group Chemical group 0.000 claims description 8
125000004429 atom Chemical group 0.000 claims description 8
125000000623 heterocyclic group Chemical group 0.000 claims description 8
230000009467 reduction Effects 0.000 claims description 8
XRSKRSVTUVLURN-UHFFFAOYSA-N 1,3-benzodioxol-4-ol Chemical group OC1=CC=CC2=C1OCO2 XRSKRSVTUVLURN-UHFFFAOYSA-N 0.000 claims description 7
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 7
238000001212 derivatisation Methods 0.000 claims description 7
JNEGMBHBUAJRSX-SHUHUVMISA-N saframycin a Chemical compound C([C@H](N1C)[C@@H]2C#N)C(C(C(C)=C(OC)C3=O)=O)=C3[C@@H]1[C@H](C1)N2[C@@H](CNC(=O)C(C)=O)C2=C1C(=O)C(C)=C(OC)C2=O JNEGMBHBUAJRSX-SHUHUVMISA-N 0.000 claims description 7
230000010933 acylation Effects 0.000 claims description 6
238000005917 acylation reaction Methods 0.000 claims description 6
LGRLWUINFJPLSH-UHFFFAOYSA-N methanide Chemical compound [CH3-] LGRLWUINFJPLSH-UHFFFAOYSA-N 0.000 claims description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
YMAUZYADYYYPHZ-UHFFFAOYSA-N Ecteinascidin 770 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(C#N)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C YMAUZYADYYYPHZ-UHFFFAOYSA-N 0.000 claims description 5
AZDDAJXLYMVMAW-FKTFMUQYSA-N Safracin A Natural products O=C(NC[C@@H]1N2[C@H]([C@@H]3N(C)[C@H](C2)Cc2c3c(O)c(OC)c(C)c2)CC=2C(=O)C(C)=C(OC)C(=O)C1=2)[C@@H](N)C AZDDAJXLYMVMAW-FKTFMUQYSA-N 0.000 claims description 5
AZDDAJXLYMVMAW-BVFBRMCBSA-N safracin a Chemical compound C([C@@H](N1C)C2)C3=CC(C)=C(OC)C(O)=C3[C@H]1[C@H](C1)N2[C@@H](CNC(=O)[C@H](C)N)C2=C1C(=O)C(C)=C(OC)C2=O AZDDAJXLYMVMAW-BVFBRMCBSA-N 0.000 claims description 5
ZGVLLWBYFNMAOM-UHFFFAOYSA-N ac1l51xm Chemical compound C1C(N2C)CC(C(C(C)=C(OC)C3=O)=O)=C3C2C(C2)N1C(CNC(=O)C(C)O)C1=C2C(=O)C(C)=C(OC)C1=O ZGVLLWBYFNMAOM-UHFFFAOYSA-N 0.000 claims description 4
125000000524 functional group Chemical group 0.000 claims description 4
230000000269 nucleophilic effect Effects 0.000 claims description 4
LMKHFHFSEWJQID-UHFFFAOYSA-N Saframycin B Natural products COC1=C(C)C(=O)C2=C(CC3C4N(C)C(CN3C2CNC(=O)C(=O)C)CC5=C4C(=O)C(=C(C)C5=O)OC)C1=O LMKHFHFSEWJQID-UHFFFAOYSA-N 0.000 claims description 3
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 3
125000002947 alkylene group Chemical group 0.000 claims description 3
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 3
239000003054 catalyst Substances 0.000 claims description 3
125000002697 cystyl group Chemical group 0.000 claims description 3
FKBKETJRCKZDAM-SDBDLDFRSA-N decyano-saframycin a Chemical compound C([C@@H](N1C)[C@@H]2O)C(C(C(C)=C(OC)C3=O)=O)=C3[C@H]1[C@H](C1)N2[C@@H](CNC(=O)C(C)=O)C2=C1C(=O)C(C)=C(OC)C2=O FKBKETJRCKZDAM-SDBDLDFRSA-N 0.000 claims description 3
238000006073 displacement reaction Methods 0.000 claims description 3
BGFXHQYUWCGGLL-QWIBJBKUSA-N ecteinascidin 770 Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](C#N)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 BGFXHQYUWCGGLL-QWIBJBKUSA-N 0.000 claims description 3
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 3
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 3
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims description 3
229950003188 isovaleryl diethylamide Drugs 0.000 claims description 3
UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
125000000405 phenylalanyl group Chemical group 0.000 claims description 3
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
KOHPLTGVBZMVDW-BBTHKVSRSA-N saframycin b Chemical compound C([C@@H](N1C)C2)C(C(C(C)=C(OC)C3=O)=O)=C3[C@H]1[C@H](C1)N2[C@@H](CNC(=O)C(C)=O)C2=C1C(=O)C(C)=C(OC)C2=O KOHPLTGVBZMVDW-BBTHKVSRSA-N 0.000 claims description 3
GATZXGIUISULHU-WDDJOWQOSA-N saframycin r Chemical group C([C@@H](N1C)[C@@H]2C#N)C3=C(O)C(C)=C(OC)C(OC(=O)CO)=C3[C@H]1[C@H](C1)N2[C@@H](CNC(=O)C(C)=O)C2=C1C(=O)C(C)=C(OC)C2=O GATZXGIUISULHU-WDDJOWQOSA-N 0.000 claims description 3
238000006467 substitution reaction Methods 0.000 claims description 3
QSLZNGPMBOCIAZ-QSNGQZDXSA-N 113036-78-5 Chemical compound C12=C(O)C(OC)=C(C)C(O)=C2[C@H](OC)[C@H]2N(C)[C@@H]1[C@H](CC=1C(C(C)=C(OC)C(=O)C=1[C@@H]1CNC(=O)[C@H](C)N)=O)N1[C@H]2O QSLZNGPMBOCIAZ-QSNGQZDXSA-N 0.000 claims description 2
HBULEGBKIIJRCH-UHFFFAOYSA-N Renieramycin B Natural products O=C1C(C)=C(OC)C(=O)C2=C1C(OCC)C1CN3C(COC(=O)C(C)=CC)C(C(=O)C(OC)=C(C)C4=O)=C4CC3C2N1C HBULEGBKIIJRCH-UHFFFAOYSA-N 0.000 claims description 2
HHQBCXAQIYVYGF-UHFFFAOYSA-N Renieramycin D Natural products O=C1C(C)=C(OC)C(=O)C2=C1C(OCC)C1C(=O)N3C(COC(=O)C(C)=CC)C(C(=O)C(OC)=C(C)C4=O)=C4CC3C2N1C HHQBCXAQIYVYGF-UHFFFAOYSA-N 0.000 claims description 2
BGHIUZDGPHSOIT-UHFFFAOYSA-N Renieramycin E Natural products OC1C(N2C)CC(C(C(C)=C(OC)C3=O)=O)=C3C2C(C2)N1C(COC(=O)C(C)=CC)C1=C2C(=O)C(C)=C(OC)C1=O BGHIUZDGPHSOIT-UHFFFAOYSA-N 0.000 claims description 2
WVBLIKAXDJHLIE-UHFFFAOYSA-N Saframycin C Natural products COC1C2CN3C(CC4=C(C3CNC(=O)C(=O)C)C(=O)C(=C(OC)C4=O)C)C(N2C)C5=C1C(=O)C(=C(OC)C5=O)C WVBLIKAXDJHLIE-UHFFFAOYSA-N 0.000 claims description 2
YQQUMADRNAOVHP-UHFFFAOYSA-N Saframycin G Natural products CN1C(C2C#N)C(O)C(C(C(C)=C(OC)C3=O)=O)=C3C1C(C1)N2C(CNC(=O)C(C)=O)C2=C1C(=O)C(C)=C(OC)C2=O YQQUMADRNAOVHP-UHFFFAOYSA-N 0.000 claims description 2
QSLZNGPMBOCIAZ-UHFFFAOYSA-N Saframycin Mx 1 Natural products C12=C(O)C(OC)=C(C)C(O)=C2C(OC)C2N(C)C1C(CC=1C(C(C)=C(OC)C(=O)C=1C1CNC(=O)C(C)N)=O)N1C2O QSLZNGPMBOCIAZ-UHFFFAOYSA-N 0.000 claims description 2
UFWYPWFCNWILJC-UHFFFAOYSA-N Saframycin Mx 2 Natural products COC1C2CN3C(CC4=C(C3CNC(=O)C(C)N)C(=O)C(=C(C)C4=O)OC)C(N2C)c5c(O)c(OC)c(C)c(O)c15 UFWYPWFCNWILJC-UHFFFAOYSA-N 0.000 claims description 2
KLKJKXQSKPPFSJ-UHFFFAOYSA-N Saframycin Y3 Natural products CN1C(C2C#N)CC(C(C(C)=C(OC)C3=O)=O)=C3C1C(C1)N2C(CNC(=O)C(C)N)C2=C1C(=O)C(C)=C(OC)C2=O KLKJKXQSKPPFSJ-UHFFFAOYSA-N 0.000 claims description 2
DULAUWVTCHNVOZ-UHFFFAOYSA-N Saframycin YD-2 Natural products CN1C(C2C#N)CC(C(C(C)=C(OC)C3=O)=O)=C3C1C(C1)N2C(CNC(=O)CN)C2=C1C(=O)C(C)=C(OC)C2=O DULAUWVTCHNVOZ-UHFFFAOYSA-N 0.000 claims description 2
125000004442 acylamino group Chemical group 0.000 claims description 2
125000004423 acyloxy group Chemical group 0.000 claims description 2
125000004104 aryloxy group Chemical group 0.000 claims description 2
125000004181 carboxyalkyl group Chemical group 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
125000005844 heterocyclyloxy group Chemical group 0.000 claims description 2
125000001165 hydrophobic group Chemical group 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
VHXCHPIQWWKYPI-UHFFFAOYSA-N renieramycin C Natural products CN1C(C2=O)C(O)C(C(C(C)=C(OC)C3=O)=O)=C3C1C(C1)N2C(COC(=O)C(C)=CC)C2=C1C(=O)C(C)=C(OC)C2=O VHXCHPIQWWKYPI-UHFFFAOYSA-N 0.000 claims description 2
JIJFDUYXCLTCFT-FZLBTGRLSA-N saframycin c Chemical compound O=C1C(C)=C(OC)C(=O)C2=C1[C@H](OC)[C@H]1CN3[C@@H](CNC(=O)C(C)=O)C(C(=O)C(OC)=C(C)C4=O)=C4C[C@H]3[C@@H]2N1C JIJFDUYXCLTCFT-FZLBTGRLSA-N 0.000 claims description 2
JRGSNFZUTBSLSG-ZKNHNOBHSA-N saframycin d Chemical compound C1([C@@H]([C@@H]2C3)N4C)=C(O)C(OC)=C(C)C(O)=C1C(=O)[C@@H]4CN2[C@@H](CNC(=O)C(C)=O)C1=C3C(=O)C(C)=C(OC)C1=O JRGSNFZUTBSLSG-ZKNHNOBHSA-N 0.000 claims description 2
WDQZQIAZHSHOFD-UHFFFAOYSA-N saframycin f Chemical compound CN1C(C2C#N)C(=O)C3=C(O)C(C)=C(OC)C(O)=C3C1C(C1)N2C(CNC(=O)C(C)=O)C2=C1C(=O)C(C)=C(OC)C2=O WDQZQIAZHSHOFD-UHFFFAOYSA-N 0.000 claims description 2
YQQUMADRNAOVHP-SEBJRLBMSA-N saframycin g Chemical compound O=C1C(OC)=C(C)C(=O)C([C@H](O)[C@H](N2C)C3C#N)=C1[C@@H]2[C@H](C1)N3[C@@H](CNC(=O)C(C)=O)C2=C1C(=O)C(C)=C(OC)C2=O YQQUMADRNAOVHP-SEBJRLBMSA-N 0.000 claims description 2
PYOFDRKUKHPATO-JLUOOAMSSA-N saframycin h Chemical compound C([C@H](N1C)C2C#N)C(C(C(C)=C(OC)C3=O)=O)=C3[C@@H]1[C@H](C1)N2[C@@H](CNC(=O)C(C)(O)CC(C)=O)C2=C1C(=O)C(C)=C(OC)C2=O PYOFDRKUKHPATO-JLUOOAMSSA-N 0.000 claims description 2
KLKJKXQSKPPFSJ-XFPFBUNZSA-N saframycin y3 Chemical compound C([C@@H](N1C)C2C#N)C(C(C(C)=C(OC)C3=O)=O)=C3[C@H]1[C@H](C1)N2[C@@H](CNC(=O)[C@H](C)N)C2=C1C(=O)C(C)=C(OC)C2=O KLKJKXQSKPPFSJ-XFPFBUNZSA-N 0.000 claims description 2
DULAUWVTCHNVOZ-FSCDNRMKSA-N saframycin-yd2 Chemical compound C([C@@H](N1C)C2C#N)C(C(C(C)=C(OC)C3=O)=O)=C3[C@H]1[C@H](C1)N2[C@@H](CNC(=O)CN)C2=C1C(=O)C(C)=C(OC)C2=O DULAUWVTCHNVOZ-FSCDNRMKSA-N 0.000 claims description 2
125000001980 alanyl group Chemical group 0.000 claims 3
XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
125000004744 butyloxycarbonyl group Chemical group 0.000 claims 1
125000001939 glutaminyl group Chemical group 0.000 claims 1
125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
125000001998 leucyl group Chemical group 0.000 claims 1
125000001288 lysyl group Chemical group 0.000 claims 1
125000002073 methionyl group Chemical group 0.000 claims 1
125000002072 seryl group Chemical group 0.000 claims 1
150000003573 thiols Chemical group 0.000 claims 1
125000001239 threonyl group Chemical group 0.000 claims 1
125000002233 tyrosyl group Chemical group 0.000 claims 1
125000002114 valyl group Chemical group 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 294
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 156
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 129
239000000243 solution Substances 0.000 description 108
238000005481 NMR spectroscopy Methods 0.000 description 106
235000019439 ethyl acetate Nutrition 0.000 description 105
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 88
239000011541 reaction mixture Substances 0.000 description 70
239000007787 solid Substances 0.000 description 63
239000000543 intermediate Substances 0.000 description 61
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 58
239000012044 organic layer Substances 0.000 description 52
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 50
238000012546 transfer Methods 0.000 description 50
238000003818 flash chromatography Methods 0.000 description 48
229910052938 sodium sulfate Inorganic materials 0.000 description 48
235000011152 sodium sulphate Nutrition 0.000 description 48
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 46
239000000203 mixture Substances 0.000 description 45
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 44
229910004298 SiO 2 Inorganic materials 0.000 description 41
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 39
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 38
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 36
229910000041 hydrogen chloride Inorganic materials 0.000 description 36
230000002829 reductive effect Effects 0.000 description 32
238000004519 manufacturing process Methods 0.000 description 28
239000002904 solvent Substances 0.000 description 27
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 26
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 19
239000003814 drug Substances 0.000 description 19
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 19
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 18
229940079593 drug Drugs 0.000 description 18
QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 18
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
229920006395 saturated elastomer Polymers 0.000 description 16
239000000047 product Substances 0.000 description 15
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
JPOXNPPZZKNXOV-UHFFFAOYSA-N bromochloromethane Chemical compound ClCBr JPOXNPPZZKNXOV-UHFFFAOYSA-N 0.000 description 12
239000000284 extract Substances 0.000 description 12
235000017557 sodium bicarbonate Nutrition 0.000 description 12
229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 11
125000003277 amino group Chemical group 0.000 description 11
239000013067 intermediate product Substances 0.000 description 11
229940024606 amino acid Drugs 0.000 description 10
235000001014 amino acid Nutrition 0.000 description 10
235000010633 broth Nutrition 0.000 description 10
238000000605 extraction Methods 0.000 description 10
238000003756 stirring Methods 0.000 description 10
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
150000001408 amides Chemical class 0.000 description 9
239000012298 atmosphere Substances 0.000 description 9
239000012074 organic phase Substances 0.000 description 9
229940117953 phenylisothiocyanate Drugs 0.000 description 9
DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 9
229930183496 Safracin Natural products 0.000 description 8
PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
125000004122 cyclic group Chemical group 0.000 description 8
239000012467 final product Substances 0.000 description 8
239000002609 medium Substances 0.000 description 8
238000000746 purification Methods 0.000 description 8
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 7
QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 7
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 7
239000012346 acetyl chloride Substances 0.000 description 7
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
229910000024 caesium carbonate Inorganic materials 0.000 description 7
150000001944 cysteine derivatives Chemical class 0.000 description 7
YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 7
239000003921 oil Substances 0.000 description 7
238000006722 reduction reaction Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 6
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
101710134784 Agnoprotein Proteins 0.000 description 6
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
229930195725 Mannitol Natural products 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
241000243142 Porifera Species 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
230000002378 acidificating effect Effects 0.000 description 6
UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Natural products NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 6
125000005110 aryl thio group Chemical group 0.000 description 6
JAMFGQBENKSWOF-UHFFFAOYSA-N bromo(methoxy)methane Chemical compound COCBr JAMFGQBENKSWOF-UHFFFAOYSA-N 0.000 description 6
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
229940125846 compound 25 Drugs 0.000 description 6
239000012043 crude product Substances 0.000 description 6
238000000855 fermentation Methods 0.000 description 6
230000004151 fermentation Effects 0.000 description 6
230000012010 growth Effects 0.000 description 6
239000000594 mannitol Substances 0.000 description 6
235000010355 mannitol Nutrition 0.000 description 6
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
ISULZYQDGYXDFW-UHFFFAOYSA-N 3-methylbutanoyl chloride Chemical compound CC(C)CC(Cl)=O ISULZYQDGYXDFW-UHFFFAOYSA-N 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
241000187389 Streptomyces lavendulae Species 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
239000012267 brine Substances 0.000 description 5
230000008859 change Effects 0.000 description 5
230000007062 hydrolysis Effects 0.000 description 5
238000006460 hydrolysis reaction Methods 0.000 description 5
150000002440 hydroxy compounds Chemical class 0.000 description 5
238000001802 infusion Methods 0.000 description 5
239000010410 layer Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical group [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 5
239000011734 sodium Substances 0.000 description 5
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
239000000725 suspension Substances 0.000 description 5
229910001868 water Inorganic materials 0.000 description 5
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 4
WOGITNXCNOTRLK-VOTSOKGWSA-N (e)-3-phenylprop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=CC=C1 WOGITNXCNOTRLK-VOTSOKGWSA-N 0.000 description 4
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 4
JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 4
229960000549 4-dimethylaminophenol Drugs 0.000 description 4
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
229940126657 Compound 17 Drugs 0.000 description 4
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 4
241000276498 Pollachius virens Species 0.000 description 4
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
241000589540 Pseudomonas fluorescens Species 0.000 description 4
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 4
125000003342 alkenyl group Chemical group 0.000 description 4
230000000259 anti-tumor effect Effects 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
229940127204 compound 29 Drugs 0.000 description 4
229940126214 compound 3 Drugs 0.000 description 4
WFPZPJSADLPSON-UHFFFAOYSA-N dinitrogen tetraoxide Chemical compound [O-][N+](=O)[N+]([O-])=O WFPZPJSADLPSON-UHFFFAOYSA-N 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
238000002156 mixing Methods 0.000 description 4
IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 4
239000012071 phase Substances 0.000 description 4
150000002989 phenols Chemical class 0.000 description 4
125000004151 quinonyl group Chemical group 0.000 description 4
230000007017 scission Effects 0.000 description 4
241000894007 species Species 0.000 description 4
238000001308 synthesis method Methods 0.000 description 4
MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 4
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
229940126639 Compound 33 Drugs 0.000 description 3
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
125000004183 alkoxy alkyl group Chemical group 0.000 description 3
BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 3
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
229910052921 ammonium sulfate Inorganic materials 0.000 description 3
235000011130 ammonium sulphate Nutrition 0.000 description 3
230000003698 anagen phase Effects 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
239000002518 antifoaming agent Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
229940126142 compound 16 Drugs 0.000 description 3
229940125782 compound 2 Drugs 0.000 description 3
229940126086 compound 21 Drugs 0.000 description 3
229940127113 compound 57 Drugs 0.000 description 3
239000006071 cream Substances 0.000 description 3
125000000753 cycloalkyl group Chemical group 0.000 description 3
238000010511 deprotection reaction Methods 0.000 description 3
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
229960003957 dexamethasone Drugs 0.000 description 3
239000008121 dextrose Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
150000002148 esters Chemical group 0.000 description 3
230000006870 function Effects 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000011534 incubation Methods 0.000 description 3
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
230000000813 microbial effect Effects 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
238000004264 monolayer culture Methods 0.000 description 3
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
239000012047 saturated solution Substances 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
229910001961 silver nitrate Inorganic materials 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
235000010288 sodium nitrite Nutrition 0.000 description 3
230000001954 sterilising effect Effects 0.000 description 3
238000004659 sterilization and disinfection Methods 0.000 description 3
229960004441 tyrosine Drugs 0.000 description 3
UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
MAKMQGKJURAJEN-RUZDIDTESA-N (2r)-1-benzyl-n-(3-spiro[1h-2-benzofuran-3,4'-piperidine]-1'-ylpropyl)pyrrolidine-2-carboxamide Chemical compound C([C@@H]1C(NCCCN2CCC3(CC2)C2=CC=CC=C2CO3)=O)CCN1CC1=CC=CC=C1 MAKMQGKJURAJEN-RUZDIDTESA-N 0.000 description 2
IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 2
YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
HGQSKTQYEWJJRZ-SNAWJCMRSA-N (e)-3-[3-(trifluoromethyl)phenyl]prop-2-enoyl chloride Chemical compound FC(F)(F)C1=CC=CC(\C=C\C(Cl)=O)=C1 HGQSKTQYEWJJRZ-SNAWJCMRSA-N 0.000 description 2
KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 2
PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 2
LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
WJXQFVMTIGJBFX-UHFFFAOYSA-N 4-methoxytyramine Chemical compound COC1=CC=C(CCN)C=C1O WJXQFVMTIGJBFX-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 2
OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 2
101100400999 Caenorhabditis elegans mel-28 gene Proteins 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
239000006145 Eagle's minimal essential medium Substances 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 2
229930012538 Paclitaxel Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
238000005273 aeration Methods 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
125000004948 alkyl aryl alkyl group Chemical group 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
239000012300 argon atmosphere Substances 0.000 description 2
125000003435 aroyl group Chemical group 0.000 description 2
125000005251 aryl acyl group Chemical group 0.000 description 2
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
150000004657 carbamic acid derivatives Chemical class 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000005352 clarification Methods 0.000 description 2
229940126543 compound 14 Drugs 0.000 description 2
229940125758 compound 15 Drugs 0.000 description 2
229940125810 compound 20 Drugs 0.000 description 2
229940126208 compound 22 Drugs 0.000 description 2
229940125833 compound 23 Drugs 0.000 description 2
229940125961 compound 24 Drugs 0.000 description 2
229940125851 compound 27 Drugs 0.000 description 2
229940125877 compound 31 Drugs 0.000 description 2
229940125878 compound 36 Drugs 0.000 description 2
229940125807 compound 37 Drugs 0.000 description 2
229940125936 compound 42 Drugs 0.000 description 2
229940125844 compound 46 Drugs 0.000 description 2
229940125898 compound 5 Drugs 0.000 description 2
229940126545 compound 53 Drugs 0.000 description 2
239000010779 crude oil Substances 0.000 description 2
125000004966 cyanoalkyl group Chemical group 0.000 description 2
150000003950 cyclic amides Chemical class 0.000 description 2
125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000020176 deacylation Effects 0.000 description 2
238000005947 deacylation reaction Methods 0.000 description 2
230000017858 demethylation Effects 0.000 description 2
238000010520 demethylation reaction Methods 0.000 description 2
125000004663 dialkyl amino group Chemical group 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000003480 eluent Substances 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229960002743 glutamine Drugs 0.000 description 2
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
125000001188 haloalkyl group Chemical group 0.000 description 2
125000002034 haloarylalkyl group Chemical group 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
125000000687 hydroquinonyl group Chemical group C1(O)=C(C=C(O)C=C1)* 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
150000002596 lactones Chemical class 0.000 description 2
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
239000007758 minimum essential medium Substances 0.000 description 2
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000001301 oxygen Chemical group 0.000 description 2
229910052760 oxygen Chemical group 0.000 description 2
229960001592 paclitaxel Drugs 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
FHPZOWOEILXXBD-UHFFFAOYSA-N phenylseleninyl benzeneseleninate Chemical compound C=1C=CC=CC=1[Se](=O)O[Se](=O)C1=CC=CC=C1 FHPZOWOEILXXBD-UHFFFAOYSA-N 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
239000001103 potassium chloride Substances 0.000 description 2
235000011164 potassium chloride Nutrition 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 2
238000010916 retrosynthetic analysis Methods 0.000 description 2
125000006413 ring segment Chemical group 0.000 description 2
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
239000008259 solid foam Substances 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
230000000707 stereoselective effect Effects 0.000 description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
238000005891 transamination reaction Methods 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
230000007306 turnover Effects 0.000 description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
238000005406 washing Methods 0.000 description 2
239000011701 zinc Substances 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
XQZOGOCTPKFYKC-VSZULPIASA-N (2r)-n-[(3s,6s,8s,12s,13r,16s,17r,20s,23s)-13-[(2s)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]-4-methyl-2-(m Chemical compound C([C@H]1C(=O)O[C@H](C)[C@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N1C)C(C)C)O)[C@@H](C)CC)C1=CC=C(OC)C=C1 XQZOGOCTPKFYKC-VSZULPIASA-N 0.000 description 1
OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 1
FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
DJMOXMNDXFFONV-UHFFFAOYSA-N 1,3-dimethyl-7-[2-(n-methylanilino)ethyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCN(C)C1=CC=CC=C1 DJMOXMNDXFFONV-UHFFFAOYSA-N 0.000 description 1
KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
SPANWYRAXDECQJ-UHFFFAOYSA-M 1-methyl-2h-pyridin-1-ium-1-carbaldehyde;chloride Chemical compound [Cl-].O=C[N+]1(C)CC=CC=C1 SPANWYRAXDECQJ-UHFFFAOYSA-M 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
YQHJFPFNGVDEDT-UHFFFAOYSA-N 2-tert-butyl-1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(N(C)C)=NC(C)(C)C YQHJFPFNGVDEDT-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 1
CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
XLWTWYHACDMFOV-UHFFFAOYSA-N 4-(9H-fluoren-9-yl)-2-(methoxymethoxy)but-2-enethioic S-acid Chemical compound COCOC(C(=S)O)=CCC1C2=CC=CC=C2C=2C=CC=CC12 XLWTWYHACDMFOV-UHFFFAOYSA-N 0.000 description 1
WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
WIDDOXWCZPPHAX-UHFFFAOYSA-N 4a,5,6,7-tetrahydro-4h-isoquinoline-1,3-dione Chemical compound C1CCC=C2C(=O)NC(=O)CC21 WIDDOXWCZPPHAX-UHFFFAOYSA-N 0.000 description 1
QGNQEODJYRGEJX-UHFFFAOYSA-N 4h-isoquinoline-1,3-dione Chemical class C1=CC=C2C(=O)NC(=O)CC2=C1 QGNQEODJYRGEJX-UHFFFAOYSA-N 0.000 description 1
SGNZYJXNUURYCH-UHFFFAOYSA-N 5,6-dihydroxyindole Chemical compound C1=C(O)C(O)=CC2=C1NC=C2 SGNZYJXNUURYCH-UHFFFAOYSA-N 0.000 description 1
XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
FMXSYRBHGUMFBA-UHFFFAOYSA-N 6-amino-3-azaniumylidene-9-[2-carboxy-4-[6-[4-[4-[4-[4-[3-carboxy-6-[4-(trifluoromethyl)phenyl]naphthalen-1-yl]phenyl]piperidin-1-yl]butyl]triazol-1-yl]hexylcarbamoyl]phenyl]-5-sulfoxanthene-4-sulfonate Chemical compound Nc1ccc2c(-c3ccc(cc3C(O)=O)C(=O)NCCCCCCn3cc(CCCCN4CCC(CC4)c4ccc(cc4)-c4cc(cc5cc(ccc45)-c4ccc(cc4)C(F)(F)F)C(O)=O)nn3)c3ccc(=[NH2+])c(c3oc2c1S(O)(=O)=O)S([O-])(=O)=O FMXSYRBHGUMFBA-UHFFFAOYSA-N 0.000 description 1
WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
108010023063 Bacto-peptone Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
241000238424 Crustacea Species 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
238000011765 DBA/2 mouse Methods 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
108010069236 Goserelin Proteins 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
241000134253 Lanka Species 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241000863422 Myxococcus xanthus Species 0.000 description 1
LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
241000187654 Nocardia Species 0.000 description 1
108010016076 Octreotide Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
MAZLTHBYATZOCX-UHFFFAOYSA-N Renierone Natural products COC1=C(C)C(=O)c2ccnc(OC(=O)C(=C/C)C)c2C1=O MAZLTHBYATZOCX-UHFFFAOYSA-N 0.000 description 1
241000316848 Rhodococcus <scale insect> Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
229940123237 Taxane Drugs 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
101710183280 Topoisomerase Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
241000778209 Xestospongia Species 0.000 description 1
SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
KFMCPROYQLHBSO-UHFFFAOYSA-N [C].C1NCCC2=CC=CC=C12 Chemical group [C].C1NCCC2=CC=CC=C12 KFMCPROYQLHBSO-UHFFFAOYSA-N 0.000 description 1
ATPPXCUZTOKZDO-UHFFFAOYSA-N [Fe].C1(O)=C(O)C(=CC=C1)C(=O)N Chemical compound [Fe].C1(O)=C(O)C(=CC=C1)C(=O)N ATPPXCUZTOKZDO-UHFFFAOYSA-N 0.000 description 1
PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
125000004945 acylaminoalkyl group Chemical group 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
125000005103 alkyl silyl group Chemical group 0.000 description 1
125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
125000005336 allyloxy group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000003602 anti-herpes Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000002927 anti-mitotic effect Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
229940124691 antibody therapeutics Drugs 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960003121 arginine Drugs 0.000 description 1
125000005018 aryl alkenyl group Chemical group 0.000 description 1
125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
125000005164 aryl thioalkyl group Chemical group 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
125000005335 azido alkyl group Chemical group 0.000 description 1
HSVLGIFAXFDLMU-UHFFFAOYSA-M benzenesulfonate;1-methylpyridin-1-ium-4-carbaldehyde Chemical compound C[N+]1=CC=C(C=O)C=C1.[O-]S(=O)(=O)C1=CC=CC=C1 HSVLGIFAXFDLMU-UHFFFAOYSA-M 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001728 carbonyl compounds Chemical class 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
125000004965 chloroalkyl group Chemical group 0.000 description 1
IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
229910052681 coesite Inorganic materials 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940127573 compound 38 Drugs 0.000 description 1
229940127271 compound 49 Drugs 0.000 description 1
229940125900 compound 59 Drugs 0.000 description 1
238000012937 correction Methods 0.000 description 1
229910052906 cristobalite Inorganic materials 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229960002433 cysteine Drugs 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
230000003436 cytoskeletal effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 1
125000004986 diarylamino group Chemical group 0.000 description 1
HDMDJEKUPKOGNK-UHFFFAOYSA-N dibromo(methoxy)methane Chemical compound COC(Br)Br HDMDJEKUPKOGNK-UHFFFAOYSA-N 0.000 description 1
FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 1
229930189582 didemnin Natural products 0.000 description 1
108010061297 didemnins Proteins 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
150000002084 enol ethers Chemical class 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
229960002074 flutamide Drugs 0.000 description 1
239000006260 foam Substances 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
229960002913 goserelin Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000004994 halo alkoxy alkyl group Chemical group 0.000 description 1
125000005252 haloacyl group Chemical group 0.000 description 1
229940022353 herceptin Drugs 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000004449 heterocyclylalkenyl group Chemical group 0.000 description 1
125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
229960002885 histidine Drugs 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
150000002537 isoquinolines Chemical class 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
229960003136 leucine Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
208000019420 lymphoid neoplasm Diseases 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
231100000682 maximum tolerated dose Toxicity 0.000 description 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
229960004961 mechlorethamine Drugs 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
231100001224 moderate toxicity Toxicity 0.000 description 1
238000007040 multi-step synthesis reaction Methods 0.000 description 1
XWCCTMBMQUCLSI-UHFFFAOYSA-N n-ethyl-n-propylpropan-1-amine Chemical compound CCCN(CC)CCC XWCCTMBMQUCLSI-UHFFFAOYSA-N 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
150000002825 nitriles Chemical group 0.000 description 1
125000004999 nitroaryl group Chemical group 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical class NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
239000012434 nucleophilic reagent Substances 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
229960002700 octreotide Drugs 0.000 description 1
229950004864 olamine Drugs 0.000 description 1
PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
229960001756 oxaliplatin Drugs 0.000 description 1
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
229960002340 pentostatin Drugs 0.000 description 1
230000008447 perception Effects 0.000 description 1
ZQWVNXAFHUXDAX-UHFFFAOYSA-N phenol;1,2,3,4-tetrahydroisoquinoline Chemical class OC1=CC=CC=C1.C1=CC=C2CNCCC2=C1 ZQWVNXAFHUXDAX-UHFFFAOYSA-N 0.000 description 1
DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
229960005190 phenylalanine Drugs 0.000 description 1
125000005544 phthalimido group Chemical group 0.000 description 1
239000006187 pill Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 description 1
108010049948 plitidepsin Proteins 0.000 description 1
229950008499 plitidepsin Drugs 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
150000003138 primary alcohols Chemical group 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
239000013587 production medium Substances 0.000 description 1
229960002429 proline Drugs 0.000 description 1
CAEWJEXPFKNBQL-UHFFFAOYSA-N prop-2-enyl carbonochloridate Chemical compound ClC(=O)OCC=C CAEWJEXPFKNBQL-UHFFFAOYSA-N 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
239000002718 pyrimidine nucleoside Substances 0.000 description 1
JGSPEFLRDJUZIE-WEVVVXLNSA-N renierone Chemical compound C1=NC(COC(=O)C(\C)=C\C)=C2C(=O)C(OC)=C(C)C(=O)C2=C1 JGSPEFLRDJUZIE-WEVVVXLNSA-N 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000011218 seed culture Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229960001153 serine Drugs 0.000 description 1
230000008054 signal transmission Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
229910052682 stishovite Inorganic materials 0.000 description 1
229960002385 streptomycin sulfate Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000004964 sulfoalkyl group Chemical group 0.000 description 1
239000011593 sulfur Chemical group 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229960002898 threonine Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000006257 total synthesis reaction Methods 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
229910052905 tridymite Inorganic materials 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Substances C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
239000003744 tubulin modulator Substances 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000009489 vacuum treatment Methods 0.000 description 1
229960004295 valine Drugs 0.000 description 1
239000004474 valine Substances 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
239000003643 water by type Substances 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Steroid Compounds (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20015547A 1999-05-14 2001-11-13 Anvendelse av utgangsmaterialer,fremgangsmate for hemisyntese av forbindelser og nye forbindelser NO322016B1 (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GBGB9911345.8A GB9911345D0 (de)	1999-05-14	1999-05-14
GBGB9918178.6A GB9918178D0 (en)	2000-05-15	1999-08-02	Synthetic methods
GBGB9923632.5A GB9923632D0 (en)	1999-10-06	1999-10-06	Hemisynthetic process towards ecteinascidin and phtalscidin compounds
GB0001063A GB0001063D0 (en)	2000-01-17	2000-01-17	Hemisynthetic process towards ecteinascidin and phtalascidin
PCT/GB2000/001852 WO2000069862A2 (en)	1999-05-14	2000-05-15	Hemisynthetic method and intermediates thereof

Publications (3)

Publication Number	Publication Date
NO20015547D0 NO20015547D0 (no)	2001-11-13
NO20015547L NO20015547L (no)	2002-01-14
NO322016B1 true NO322016B1 (no)	2006-08-07

Family

ID=42632476

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20015547A NO322016B1 (no)	1999-05-14	2001-11-13	Anvendelse av utgangsmaterialer,fremgangsmate for hemisyntese av forbindelser og nye forbindelser
NO20025186A NO328301B1 (no)	1999-05-14	2002-10-29	Fremgangsmate for syntese av en ecteinascidinforbindelse

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20025186A NO328301B1 (no)	1999-05-14	2002-10-29	Fremgangsmate for syntese av en ecteinascidinforbindelse

Country Status (29)

Country	Link
US (3)	US7241892B1 (de)
EP (1)	EP1185536B1 (de)
JP (1)	JP4445136B2 (de)
KR (1)	KR100834601B1 (de)
CN (3)	CN1229382C (de)
AR (1)	AR035842A1 (de)
AT (1)	ATE283273T1 (de)
AU (2)	AU775580B2 (de)
BG (1)	BG65896B1 (de)
BR (3)	BRPI0010559B8 (de)
CA (2)	CA2372058C (de)
CY (1)	CY1108095T1 (de)
CZ (3)	CZ303536B6 (de)
DE (1)	DE60016209T2 (de)
DK (1)	DK1185536T3 (de)
ES (2)	ES2233367T3 (de)
HU (1)	HU230646B1 (de)
MX (1)	MXPA01011631A (de)
MY (1)	MY130271A (de)
NO (2)	NO322016B1 (de)
NZ (1)	NZ515424A (de)
PL (1)	PL226890B1 (de)
PT (1)	PT1185536E (de)
RU (1)	RU2237063C9 (de)
SI (2)	SI1185536T1 (de)
SK (2)	SK287835B6 (de)
TR (1)	TR200103273T2 (de)
UA (1)	UA75333C2 (de)
WO (3)	WO2000069862A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2331593C (en)	1998-05-11	2008-08-05	Pharma Mar, S.A.	Metabolites of ecteinascidin 743
MY164077A (en)	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
AR035842A1 (es)	1999-05-14	2004-07-21	Pharma Mar Sa	Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US7919493B2 (en)	2000-04-12	2011-04-05	Pharma Mar, S.A.	Anititumoral ecteinascidin derivatives
WO2001077115A1 (en)	2000-04-12	2001-10-18	Pharma Mar, S.A.	Antitumoral ecteinascidin derivatives
MXPA02011319A (es)	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.
NZ521808A (en) *	2000-05-15	2004-07-30	Pharma Mar S	Synthetic process for the manufacture of an ecteinaschidin compound
US7420051B2 (en)	2000-05-15	2008-09-02	Pharma Mar, S.A.	Synthetic process for the manufacture of an ecteinaschidin compound
CA2447553A1 (en)	2000-11-03	2002-05-23	President And Fellows Of Harvard College	Saframycins, analogues and uses thereof
BR0115162A (pt) *	2000-11-06	2003-10-21	Pharma Mar Sa	Tratamentos antitumorais eficazes
GB0117402D0 (en) *	2001-07-17	2001-09-05	Pharma Mar Sa	New antitumoral derivatives of et-743
GB0119243D0 (en)	2001-08-07	2001-10-03	Pharma Mar Sa	Antitumoral analogs of ET-743
PL368458A1 (en) *	2001-10-19	2005-03-21	Pharmamar S.A.	Improved use of antitumoral compound in cancer therapy
GB0202544D0 (en)	2002-02-04	2002-03-20	Pharma Mar Sa	The synthesis of naturally occuring ecteinascidins and related compounds
GB0229793D0 (en) *	2002-12-20	2003-01-29	Pharma Mar Sa	The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0312407D0 (en) *	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
US7183054B2 (en)	2003-06-03	2007-02-27	President And Fellows Of Harvard College	Assay for identifying biological targets of polynucleotide-binding compounds
GB0324201D0 (en) *	2003-10-15	2003-11-19	Pharma Mar Sau	Improved antitumoral combinations
HRP20080598T3 (en)	2003-11-13	2009-01-31	Pharma Mar	Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
AU2004291037A1 (en) *	2003-11-14	2005-06-02	Pharma Mar, S.A.	Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
AU2005288696A1 (en) *	2004-09-28	2006-04-06	Pharma Mar S.A., Sociedad Unipersonal	Ecteinascidin compounds as anti -inflammatory agents
EP1827500B1 (de) *	2004-10-26	2009-05-06	Pharma Mar S.A., Sociedad Unipersonal	Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743
ATE368461T1 (de)	2004-10-29	2007-08-15	Pharma Mar Sa	Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
GB0522082D0 (en)	2005-10-31	2005-12-07	Pharma Mar Sa	Formulations
KR100712667B1 (ko)	2006-04-11	2007-05-02	재단법인서울대학교산학협력재단	신규한 디아자 헤테로고리 유도체 및 그의 고체상 제조방법
GB0708691D0 (en) *	2007-05-04	2007-06-13	Pharma Mar Sa	Anticancer treatments a
US20090076017A1 (en) *	2007-09-15	2009-03-19	Protia, Llc	Deuterium-enriched trabectedin
US20100267732A1 (en) *	2007-10-19	2010-10-21	Pharma Mar, S.A.	Prognostic Molecular Markers for ET-743 Treatment
JP2011520921A (ja) *	2008-05-16	2011-07-21	ファルマ・マール・ソシエダード・アノニマ	抗腫瘍アルカロイドとの併用療法
NZ589270A (en) *	2008-05-16	2011-12-22	Pharma Mar Sa	Multiple myeloma treatments
WO2011048210A1 (en)	2009-10-22	2011-04-28	Pharma Mar, S.A.	PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
CN103038240A (zh) *	2010-05-25	2013-04-10	法马马有限公司	制备海鞘素化合物的合成方法
RS54648B1 (sr)	2010-11-12	2016-08-31	Pharma Mar S.A.	Kombinovana terapija sa antitumorskim alkaloidom
KR102491180B1 (ko)	2017-04-27	2023-01-20	파르마 마르 에스.에이.	항종양 화합물
CN107739387B (zh) *	2017-10-16	2020-01-03	上海皓元生物医药科技有限公司	一种制备曲贝替定的关键中间体化合物的方法
CN109912629B (zh) *	2017-12-13	2021-12-24	浙江中科创越药业有限公司	天然产物Trabectedin的制备
TWI824043B (zh)	2018-10-25	2023-12-01	西班牙商瑪製藥股份有限公司	藥物抗體共軛物
CN111518110B (zh) *	2019-02-01	2023-11-03	博瑞生物医药（苏州）股份有限公司	一种海鞘素化合物及其中间体的制备方法
CN111620792B (zh) *	2019-02-28	2023-01-03	兰州大学	一种n,n-二取代氰基甲酰胺的合成方法
PE20252386A1 (es)	2019-11-21	2025-10-10	Pharma Mar Sa	Metodo de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina
CN116217584A (zh) *	2021-12-06	2023-06-06	南通诺泰生物医药技术有限公司	Et743及其中间体的光催化合成方法
CN117659032A (zh) *	2022-08-29	2024-03-08	南通诺泰生物医药技术有限公司	海鞘素类衍生物的中间体及其的合成方法
AU2024210894A1 (en) *	2023-01-17	2025-07-17	Adcytherix Sas	Ecteinascidin derivative antibody drug conjugates
WO2025077996A1 (en)	2023-10-09	2025-04-17	Pharma Mar, S.A.	Synthetic process for the manufacture of ecteinascidin compounds
WO2025233522A1 (en)	2024-05-10	2025-11-13	Pharma Mar, S.A.	Synthetic process for an ecteinascidin
WO2026022359A2 (en)	2024-07-26	2026-01-29	Pharma Mar, S.A.	Synthetic process for the manufacture of ecteinascidin compounds
CN119613425B (zh) *	2024-10-31	2026-04-03	深圳创元生物医药科技有限公司	一种曲贝替定五环核心骨架的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2461995A1 (fr)	1979-07-20	1981-02-06	Lcc Cice Cie Europ Compo Elect	Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
JPS59225189A (ja)	1983-06-03	1984-12-18	Shionogi & Co Ltd	キノナミン誘導体およびその製造法
JPS6054386A (ja) *	1983-09-02	1985-03-28	Yoshitomi Pharmaceut Ind Ltd	サフラシン誘導体
JPS6084288A (ja)	1983-10-13	1985-05-13	Shionogi & Co Ltd	シアノキノナミンアセテ−ト類およびその製造法
US5089273A (en)	1986-06-09	1992-02-18	Board Of Trustees Of The University Of Illinois	Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en)	1986-06-09	1993-10-26	The Board Of Trustees Of The University Of Illinois	Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en)	1990-11-30	1992-09-22	The Board Of Trustees Of The University Of Illinois	Ecteinascidins 736 and 722
EP0309477B1 (de)	1986-06-09	1991-11-06	The Board Of Trustees Of The University Of Illinois	Ekteinascidine 729, 743, 745, 759a, 759b und 770
US5478932A (en)	1993-12-02	1995-12-26	The Board Of Trustees Of The University Of Illinois	Ecteinascidins
SG50747A1 (en) *	1995-08-02	1998-07-20	Tanabe Seiyaku Co	Comptothecin derivatives
US5721362A (en) *	1996-09-18	1998-02-24	President And Fellows Of Harvard College	Process for producing ecteinascidin compounds
US5985876A (en)	1997-04-15	1999-11-16	Univ Illinois	Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
BR9909488B1 (pt)	1998-04-06	2011-02-08		ecteinascidinas semi-sintéticas e composição farmacêutica.
CA2331593C (en)	1998-05-11	2008-08-05	Pharma Mar, S.A.	Metabolites of ecteinascidin 743
US6124292A (en)	1998-09-30	2000-09-26	President And Fellows Of Harvard College	Synthetic analogs of ecteinascidin-743
AR035842A1 (es)	1999-05-14	2004-07-21	Pharma Mar Sa	Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
CA2397597A1 (en)	2000-01-19	2001-07-26	The Trustees Of Columbia University In The City Of New York	Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
WO2001077115A1 (en)	2000-04-12	2001-10-18	Pharma Mar, S.A.	Antitumoral ecteinascidin derivatives
MXPA02011319A (es)	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.

2000
- 2000-05-12 AR ARP000102308A patent/AR035842A1/es active IP Right Grant
- 2000-05-12 MY MYPI20002078A patent/MY130271A/en unknown
- 2000-05-15 CA CA2372058A patent/CA2372058C/en not_active Expired - Lifetime
- 2000-05-15 PT PT00927582T patent/PT1185536E/pt unknown
- 2000-05-15 AT AT00927582T patent/ATE283273T1/de active
- 2000-05-15 RU RU2001133386/04A patent/RU2237063C9/ru active
- 2000-05-15 JP JP2000618279A patent/JP4445136B2/ja not_active Expired - Lifetime
- 2000-05-15 CN CNB008100829A patent/CN1229382C/zh not_active Expired - Lifetime
- 2000-05-15 EP EP00927582A patent/EP1185536B1/de not_active Expired - Lifetime
- 2000-05-15 WO PCT/GB2000/001852 patent/WO2000069862A2/en not_active Ceased
- 2000-05-15 HU HU0201188A patent/HU230646B1/hu unknown
- 2000-05-15 KR KR1020017014551A patent/KR100834601B1/ko not_active Expired - Lifetime
- 2000-05-15 SI SI200030599T patent/SI1185536T1/xx unknown
- 2000-05-15 SK SK1650-2001A patent/SK287835B6/sk not_active IP Right Cessation
- 2000-05-15 MX MXPA01011631A patent/MXPA01011631A/es active IP Right Grant
- 2000-05-15 BR BRPI0010559A patent/BRPI0010559B8/pt not_active IP Right Cessation
- 2000-05-15 TR TR2001/03273T patent/TR200103273T2/xx unknown
- 2000-05-15 AU AU45973/00A patent/AU775580B2/en not_active Expired
- 2000-05-15 ES ES00927582T patent/ES2233367T3/es not_active Expired - Lifetime
- 2000-05-15 CZ CZ20014102A patent/CZ303536B6/cs not_active IP Right Cessation
- 2000-05-15 DK DK00927582T patent/DK1185536T3/da active
- 2000-05-15 NZ NZ515424A patent/NZ515424A/en not_active IP Right Cessation
- 2000-05-15 UA UA2001128605A patent/UA75333C2/uk unknown
- 2000-05-15 DE DE60016209T patent/DE60016209T2/de not_active Expired - Lifetime
- 2000-05-15 US US09/979,404 patent/US7241892B1/en not_active Expired - Lifetime
- 2000-05-15 PL PL353002A patent/PL226890B1/pl unknown
2001
- 2001-05-15 BR BR0110801-8 patent/BRPI0110801B8/pt not_active IP Right Cessation
- 2001-05-15 BR BR0110443-8 patent/BRPI0110443B8/pt not_active IP Right Cessation
- 2001-05-15 CZ CZ2002-3751A patent/CZ304973B6/cs not_active IP Right Cessation
- 2001-05-15 CZ CZ2002-3746A patent/CZ304966B6/cs not_active IP Right Cessation
- 2001-05-15 CN CNB018127460A patent/CN1211386C/zh not_active Expired - Lifetime
- 2001-05-15 AU AU5649601A patent/AU5649601A/xx active Pending
- 2001-05-15 CA CA2406095A patent/CA2406095C/en not_active Expired - Lifetime
- 2001-05-15 WO PCT/GB2001/002110 patent/WO2001087894A1/en not_active Ceased
- 2001-05-15 CN CNB018120431A patent/CN100475822C/zh not_active Expired - Lifetime
- 2001-05-15 US US10/257,856 patent/US20040002602A1/en not_active Abandoned
- 2001-05-15 SI SI200130399T patent/SI1287004T1/sl unknown
- 2001-05-15 WO PCT/GB2001/002120 patent/WO2001087895A1/en not_active Ceased
- 2001-05-15 ES ES01929813T patent/ES2231486T3/es not_active Expired - Lifetime
- 2001-05-15 SK SK1527-2002A patent/SK287879B6/sk not_active IP Right Cessation
- 2001-11-13 NO NO20015547A patent/NO322016B1/no not_active IP Right Cessation
2002
- 2002-10-29 NO NO20025186A patent/NO328301B1/no not_active IP Right Cessation
- 2002-11-20 BG BG107301A patent/BG65896B1/bg unknown
2007
- 2007-07-09 US US11/774,890 patent/US7524956B2/en not_active Expired - Fee Related
- 2007-10-29 CY CY20071101392T patent/CY1108095T1/el unknown

Also Published As

Publication number	Publication date
PT1185536E (pt)	2005-04-29
CA2372058C (en)	2010-10-26
BG65896B1 (bg)	2010-04-30
SI1287004T1 (sl)	2005-12-31
NO20015547D0 (no)	2001-11-13
PL226890B1 (pl)	2017-09-29
US20080045713A1 (en)	2008-02-21
HUP0201188A2 (en)	2002-07-29
CZ20023751A3 (en)	2004-05-12
BRPI0110801B1 (pt)	2018-02-27
BRPI0110443B1 (pt)	2018-06-26
BRPI0110801B8 (pt)	2021-05-25
CA2372058A1 (en)	2000-11-23
AU4597300A (en)	2000-12-05
CA2406095C (en)	2010-02-16
NO328301B1 (no)	2010-01-25
AR035842A1 (es)	2004-07-21
BR0010559A (pt)	2002-07-02
CN100475822C (zh)	2009-04-08
DE60016209T2 (de)	2005-12-15
JP4445136B2 (ja)	2010-04-07
BRPI0110443B8 (pt)	2021-05-25
US20040002602A1 (en)	2004-01-01
CZ304966B6 (cs)	2015-02-18
US7524956B2 (en)	2009-04-28
BR0110801A (pt)	2003-02-11
BG107301A (bg)	2003-07-31
SK16502001A3 (sk)	2002-06-04
CA2406095A1 (en)	2001-11-22
EP1185536B1 (de)	2004-11-24
SK287835B6 (sk)	2011-12-05
WO2000069862A3 (en)	2001-03-22
CZ20014102A3 (cs)	2002-06-12
KR20020021636A (ko)	2002-03-21
JP2002544280A (ja)	2002-12-24
CN1229382C (zh)	2005-11-30
ATE283273T1 (de)	2004-12-15
WO2001087895A1 (en)	2001-11-22
BRPI0010559B1 (pt)	2016-08-30
HU230646B1 (hu)	2017-05-29
NZ515424A (en)	2004-06-25
CZ303536B6 (cs)	2012-11-21
ES2233367T3 (es)	2005-06-16
EP1185536A2 (de)	2002-03-13
SI1185536T1 (en)	2005-06-30
MXPA01011631A (es)	2002-07-30
NO20025186L (no)	2003-01-14
ES2231486T3 (es)	2005-05-16
WO2000069862A2 (en)	2000-11-23
MY130271A (en)	2007-06-29
WO2001087894A1 (en)	2001-11-22
SK287879B6 (sk)	2012-02-03
UA75333C2 (uk)	2006-04-17
TR200103273T2 (tr)	2002-04-22
AU5649601A (en)	2001-11-26
CN1211386C (zh)	2005-07-20
CZ20023746A3 (cs)	2003-04-16
CY1108095T1 (el)	2014-02-12
BRPI0010559B8 (pt)	2021-05-25
BR0110443A (pt)	2003-04-08
CN1441805A (zh)	2003-09-10
NO20025186D0 (no)	2002-10-29
DK1185536T3 (da)	2005-04-04
AU775580B2 (en)	2004-08-05
CN1440414A (zh)	2003-09-03
NO20015547L (no)	2002-01-14
SK15272002A3 (sk)	2003-06-03
RU2237063C9 (ru)	2008-10-10
US7241892B1 (en)	2007-07-10
RU2237063C2 (ru)	2004-09-27
HK1047432A1 (en)	2003-02-21
KR100834601B1 (ko)	2008-06-02
PL353002A1 (en)	2003-09-22
DE60016209D1 (de)	2004-12-30
CN1360588A (zh)	2002-07-24
CZ304973B6 (cs)	2015-02-25

Legal Events

Date	Code	Title	Description
2020-06-08	MK1K	Patent expired

Publication	Publication Date	Title
NO322016B1 (no)	2006-08-07	Anvendelse av utgangsmaterialer,fremgangsmate for hemisyntese av forbindelser og nye forbindelser
US7420051B2 (en)	2008-09-02	Synthetic process for the manufacture of an ecteinaschidin compound
EP1287004B1 (de)	2005-07-27	Synthetisches verfahren zur herstellung von ecteinascidin-derivaten
AU2001256496A1 (en)	2002-02-14	Synthetic process for the manufacture of an ecteinascidin compound
NO329561B1 (no)	2010-11-15	Forbindelser som er analoger av ET-743, farmasoytiske preparater som omfatter en slik forbindelse, og anvendelse av forbindelsene til fremstilling av farmasoytiske preparater for anvendelse ved behandling av tumorer
BG106216A (bg)	2002-08-30	Полусинтетичен метод и нови съединения
HK1050193B (en)	2006-03-03	Synthetic process for the manufacture of an ecteinascidin compound
IL152125A (en)	2008-04-13	Process for the manufacture of ecteinascidin derivatives